Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial.

Publisher: BioMed Central Country of Publication: England NLM ID: 101474849 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-2215 (Electronic) Linking ISSN: 17572215 NLM ISO Abbreviation: J Ovarian Res Subsets: MEDLINE

Original Publication: [London] : BioMed Central, c2008-

Phlebotomy*; Androgen Antagonists/*therapeutic use ; Contraceptives, Oral/*therapeutic use ; Cyproterone Acetate/*therapeutic use ; Polycystic Ovary Syndrome/*therapy; Adolescent ; Adult ; Androgens/blood ; Androstenedione/blood ; Cholesterol/blood ; Female ; Humans ; Insulin/blood ; Insulin Resistance ; Polycystic Ovary Syndrome/blood ; Testosterone/blood ; Triglycerides/blood ; Young Adult

Background: Reduction of the body iron stores can improve hyperandrogenemia and insulin resistance. This study aimed to compare clinical and para-clinical responses to the treatment of phlebotomy using oral contraceptive pills (OCs) containing cyproterone acetate in women with PCOS.
Methods: In this randomized clinical trial, 64 patients with PCOS were randomly assigned to the phlebotomy and OCs groups (n = 32 in each group). The intervention group, using a single treatment procedure, underwent venesection of 450 mL of whole blood at the early follicular phase of the spontaneous or progesterone-induced menstrual cycle. The control group received OCs pills for 3 months from the 1th day of spontaneous or progesterone-induced menstrual cycle onwards for 3 weeks, followed by a pill-free interval of 7 days. The women were evaluated after the 3-month intervention. The primary outcome measure was a change in the HOMA-IR and free androgen index (FAI). Secondary outcomes were changes in the Ferriman-Gallwey (FG) score and other clinical, biochemical and hormonal changes from the baseline (pre-treatment) to week 12.
Results: In the phlebotomy group, 27 (84.3%) and in the OCs group 30 (93.7%) of the women completed the 3-month follow-up. The median HOMA-IR significantly decreased from 3.5 to 2.7 in the phlebotomy, and from 3.1 to 2.8 in the OCs group, and the changes were comparable between the groups. Median changes in the FAI significantly decreased in both groups, but the differences were not statistically significant between the groups (P = 0.061). With regard to secondary outcomes, mean FG scores in both groups significantly decreased [from 16.8 (6) to 13.3 (7.4), P < 0.028] in the phlebotomy group and [from 14.3 (7) to 9.8 (7.6) in the OCs group, P = 0.001] after 3 months of treatment, but such changes had no statistically significant differences between the groups. During treatment, menstrual cycles became regular in all women in the OCs group and in 12.27 (44.4%) of the women in the phlebotomy group, and the difference was statistically significant (P = 0.001). Despite no statistically significant differences in lipid profiles between the groups at the baseline, triglycerides were significantly higher in the OCs group compared to the phlebotomy at end of follow up (p = 0.019).
Conclusion: Both treatment modalities had similar beneficial effects on insulin resistance and on androgenic profiles. However, OCs was reported more effective in treating menstrual irregularities and phlebotomy had less adverse effects on triglyceride concentrations.
Trial Registration: Code: IRCT2013080514277N1 .

Circulation. 2001 Jan 2;103(1):52-7. (PMID: 11136685)
Diabetes. 2002 Apr;51(4):1000-4. (PMID: 11916918)
Diabetes Care. 2002 Dec;25(12):2249-55. (PMID: 12453969)
Fertil Steril. 2004 Jan;81(1):19-25. (PMID: 14711538)
J Clin Endocrinol Metab. 2004 Jan;89(1):135-41. (PMID: 14715840)
Endocr Rev. 2005 Apr;26(2):251-82. (PMID: 15561799)
Diabetes Care. 2005 Aug;28(8):2042-4. (PMID: 16043756)
J Clin Endocrinol Metab. 2007 Feb;92(2):405-13. (PMID: 17090633)
Am J Gastroenterol. 2007 Jun;102(6):1251-8. (PMID: 17391316)
Diabetes Care. 2007 Jul;30(7):1926-33. (PMID: 17429063)
Diabetes Care. 2007 Sep;30(9):2309-13. (PMID: 17536071)
Diabetes Care. 2008 Jan;31(1):3-8. (PMID: 17959863)
J Clin Endocrinol Metab. 2008 Jun;93(6):2089-96. (PMID: 18334581)
Int J Obes (Lond). 2008 Nov;32(11):1665-9. (PMID: 18779821)
PLoS One. 2008;3(10):e3547. (PMID: 18958176)
J Am Coll Cardiol. 2009 Jan 20;53(3):221-31. (PMID: 19147038)
Diabetes Care. 2009 Aug;32(8):1525-30. (PMID: 19401444)
Lipids Health Dis. 2010 May 21;9:52. (PMID: 20487572)
Arch Gynecol Obstet. 2011 Oct;284(4):923-9. (PMID: 21140159)
J Clin Endocrinol Metab. 2011 Mar;96(3):846-52. (PMID: 21209031)
Reprod Biol Endocrinol. 2011 Mar 25;9:39. (PMID: 21435276)
Trends Endocrinol Metab. 2012 Oct;23(10):509-15. (PMID: 22579050)
BMC Med. 2012 May 30;10:54. (PMID: 22647517)
Clin Endocrinol (Oxf). 2013 Jan;78(1):120-5. (PMID: 22702394)
Diabetologia. 2012 Oct;55(10):2613-2621. (PMID: 22752055)
BMC Med. 2012 Oct 10;10:119. (PMID: 23046549)
Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:51-5. (PMID: 24220143)
Clin Epidemiol. 2013 Dec 18;6:1-13. (PMID: 24379699)
J Ovarian Res. 2014 Feb 07;7:18. (PMID: 24502610)
Gynecol Endocrinol. 2014;30(12):850-60. (PMID: 25254621)
J Clin Endocrinol Metab. 2015 Mar;100(3):794-802. (PMID: 25701301)
Gynecol Endocrinol. 2016;32(5):343-53. (PMID: 27052492)
PLoS One. 2016 Dec 16;11(12):e0168402. (PMID: 27992506)
Mol Metab. 2016 Oct 31;6(1):38-47. (PMID: 28123936)
J Endocrinol Invest. 2017 Aug;40(8):859-866. (PMID: 28332170)
Eur J Contracept Reprod Health Care. 2017 Jun;22(3):183-190. (PMID: 28463030)
Clin Endocrinol (Oxf). 2017 Sep;87(3):217-230. (PMID: 28575537)
Clin Endocrinol (Oxf). 2018 Feb;88(2):169-184. (PMID: 28930378)
Fertil Steril. 2017 Dec;108(6):1078-1084. (PMID: 29202960)
Open Access J Contracept. 2017 Feb 02;8:13-23. (PMID: 29386951)
Biomarkers. 2019 Jul;24(5):484-491. (PMID: 31096807)
Clin Chem. 1987 Aug;33(8):1372-5. (PMID: 3608155)
Metabolism. 1994 May;43(5):614-20. (PMID: 8177050)
J Clin Endocrinol Metab. 1993 Aug;77(2):478-83. (PMID: 8345055)
Blood. 1997 Feb 1;89(3):739-61. (PMID: 9028304)

Keywords: Cyproterone compound; Phlebotomy; Polycystic ovarian syndrome; Randomized control trial (RCT)

0 (Androgen Antagonists)
0 (Androgens)
0 (Contraceptives, Oral)
0 (Insulin)
0 (Triglycerides)
3XMK78S47O (Testosterone)
409J2J96VR (Androstenedione)
4KM2BN5JHF (Cyproterone Acetate)
97C5T2UQ7J (Cholesterol)

Date Created: 20190901 Date Completed: 20200206 Latest Revision: 20200225

20250114

PMC6716867

10.1186/s13048-019-0554-9

31470879